The increasing availability of genomic data for pathogens that cause tropical diseases has created new opportunities for drug discovery and development. However, if the potential of such data is to be fully exploited, the data must be effectively integrated and be easy to interrogate. Here, we discuss the development of the TDR Targets database (http://tdrtargets.org), which encompasses extensive genetic, biochemical and pharmacological data related to tropical disease pathogens, as well as computationally predicted druggability for potential targets and compound desirability information. By allowing the integration and weighting of this information, this database aims to facilitate the identification and prioritization of candidate drug targets for pathogens.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nature Rev. Drug Discov. 5, 941–955 (2006).
Heby, O., Persson, L. & Rentala, M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 33, 359–366 (2007).
Mori, M. et al. Contribution of structural biology to clinically validated target proteins. Drug Discov. Today 13, 469–472 (2008).
Varghese, J. N. Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev. Res. 46, 176–196 (1999).
Ghedin, E. et al. Draft genome of the filarial nematode parasite Brugia malayi. Science 317, 1756–1760 (2007).
McAdam, R. A. et al. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 148, 2975–2986 (2002).
Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77–84 (2003).
Lamichhane, G. et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 100, 7213–7218 (2003).
McNeil, L. K. et al. The National Microbial Pathogen Database Resource (NMPDR): a genomics platform based on subsystem annotation. Nucleic Acids Res. 35, D347–D353 (2007).
Chen, F., Mackey, A. J., Vermunt, J. K. & Roos, D. S. Assessing performance of orthology detection strategies applied to eukaryotic genomes. PLoS ONE 2, e383 (2007).
Chen, F., Mackey, A. J., Stoeckert, C. J. Jr & Roos, D. S. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. Nucleic Acids Res. 34, D363–D368 (2006).
Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006).
Al-Lazikani, B. et al. in Bioinformatics — From Genomes to Therapies. Volume 3: The Holy Grail: Molecular Function (ed. Lengauer, T.) 1315–1334 (Wiley-VCH, Weinheim, 2007).
Winzeler, E. A. et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285, 901–906 (1999).
Kamath, R. S. et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421, 231–237 (2003).
Gerdes, S. Y. et al. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J. Bacteriol. 185, 5673–5684 (2003).
Titus, R. G., Gueiros-Filho, F. J., de Freitas, L. A. & Beverley, S. M. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl Acad. Sci. USA 92, 10267–10271 (1995).
Chaudhary, K. et al. Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii. J. Biol. Chem. 279, 31221–31227 (2004).
Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
Pieper, U. et al. MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res. 32, D217–D222 (2004).
Paolini, G. V., Shapland, R. H., van Hoorn, W. P., Mason, J. S. & Hopkins, A. L. Global mapping of pharmacological space. Nature Biotech. 24, 805–815 (2006).
Meissner, M., Breinich, M. S., Gilson, P. R. & Crabb, B. S. Molecular genetic tools in Toxoplasma and Plasmodium: achievements and future needs. Curr. Opin. Microbiol. 10, 349–356 (2007).
Hasan, S., Daugelat, S., Rao, P. S. & Schreiber, M. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput. Biol. 2, e61 (2006).
Kumar, S. et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS ONE 2, e1189 (2007).
Hopkins, A. L., Witty, M. J. & Nwaka, S. Mission possible. Nature 449, 166–169 (2007).
Montalvetti, A. et al. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J. Biol. Chem. 278, 17075–17083 (2003).
The authors wish to acknowledge all of the investigators who provided the data in the TDR Targets database including those that participated in the survey on drug targets for Human African Trypanosomiasis (HAT survey) conducted during 2007. We would also like to acknowledge Brandeis University MS students P. Bais and B. Coflan for work on the association of targets with compounds; R. L. Stevens (Argonne National Laboratory) for providing data for gene essentiality in bacteria; K. Chaudhary and T. Carlow (New England BioLabs) for integrated C. elegans phenotype data; J. Sacchetini (Texas A&M) for information on known M. tuberculosis drug targets; and M. Schreiber (Novartis Institute for Tropical Diseases, Singapore) and J. Brown (GlaxoSmithKline) for input on integrating data on persistent expressed genes in dormant-stage M. tuberculosis infection. We would also like to acknowledge essential computational infrastructure and genome annotations made available through the OrthoMCL database (supported by the US National Institutes of Health; NIH); GeneDB (supported by the Wellcome Trust); Ensembl (supported by the European Bioinformatics Institute); and EuPathDB (supported by a Bioinformatics Resource Center contract from the US NIH/National Institute of Allergy and Infectious Diseases). The authors also gratefully acknowledge Pfizer Global Research and Development for sharing data related to druggability. This work was supported by grants from the United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.
About this article
Cite this article
Agüero, F., Al-Lazikani, B., Aslett, M. et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7, 900–907 (2008). https://doi.org/10.1038/nrd2684
Structure determination and analyses of the GAPDH from the parasite Schistosoma mansoni, the first one from a platyhelminth
De novo histidine biosynthesis protects Mycobacterium tuberculosis from host IFN-γ mediated histidine starvation
Communications Biology (2021)
Frontiers in Genetics (2021)
A computational approach to validate novel drug targets of gentianine from Swertiya chirayita in Plasmodium falciparum